论文部分内容阅读
目的探讨雷贝拉唑联合铝碳酸镁治疗胆囊切除术后伴胆汁反流性胃炎的临床疗效。方法选取2012年12月—2013年12月攀枝花市第二人民医院收治的胆囊切除后伴胆汁反流性胃炎患者172例,根据临床治疗方法不同分为研究组和对照组,各86例。研究组给予雷贝拉唑联合铝碳酸镁治疗,对照组给予雷贝拉唑治疗。观察两组患者的临床疗效以及隐痛、饱胀、嗳气、反酸等临床症状评分。结果研究组总有效率为91.86%,高于对照组的76.74%,差异有统计学意义(P<0.05)。治疗前两组患者隐痛、饱胀、嗳气和反酸临床症状评分比较,差异无统计学意义(P>0.05);治疗后研究组患者隐痛、饱胀、嗳气和反酸临床症状评分低于对照组,差异有统计学意义(P<0.05)。结论雷贝拉唑联合铝碳酸镁治疗胆囊切除术后伴胆汁反流性胃炎的临床疗效显著。
Objective To investigate the clinical efficacy of rabeprazole and aluminum magnesium carbonate in the treatment of bile reflux gastritis after cholecystectomy. Methods A total of 172 patients with bile reflux gastritis after cholecystectomy were enrolled in the Second People’s Hospital of Panzhihua City from December 2012 to December 2013. The patients were divided into study group and control group with 86 cases in each group according to different clinical treatment methods. The study group was given rabeprazole in combination with magnesium aluminum carbonate, and the control group was given rabeprazole. The clinical efficacy of the two groups were observed and scores of clinical symptoms such as pain, swelling, belching, acid reflux and so on were scored. Results The total effective rate of the study group was 91.86%, which was higher than that of the control group (76.74%), the difference was statistically significant (P <0.05). Before treatment, there was no significant difference between the two groups in the scores of pain, fullness, belching and acid reflux clinical symptom scores (P> 0.05). After treatment, the scores of clinical symptoms of pain, fullness, belching and acid reflux in the study group were lower than those in the control Group, the difference was statistically significant (P <0.05). Conclusion The rabeprazole combined with aluminum magnesium carbonate after cholecystectomy with bile reflux gastritis clinical efficacy significantly.